ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mezzetti, M.
Right arrow Articles by Conforti, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mezzetti, M.
Right arrow Articles by Conforti, S.
Related Collections
Right arrow Lung - cancer

Ann Thorac Surg 2003;76:1838-1842
© 2003 The Society of Thoracic Surgeons

Original article: general thoracic

Assessment of outcomes in typical and atypical carcinoids according to latest WHO classification

Maurizio Mezzetti, MDa*, Federico Raveglia, MDa, Tiziana Panigalli, MDa, Luigi Giuliani, MDa, Fabio Lo Giudice, MDa, Stefano Meda, MDa, Serena Conforti, MDa

a School of Specialization of Thoracic Surgery, S. Paolo Hospital, Milan, Italy

Accepted for publication June 30, 2003.

* Address reprint requests to Dr Mezzetti, Via Boccaccio 27, 20123 Milan, Italy
e-mail: maurizio.mezzetti{at}unimi.it

BACKGROUND: Pulmonary carcinoid tumors represent a group of malignant neoplasms comprised of neuroendocrine cells. In 1999, the World Health Organization (W.H.O.) proposed the definitive classification of neuroendocrine tumors based on the criteria from Travis and associates. The W.H.O. described two different groups of carcinoid tumors: typical carcinoids (TC) and atypical carcinoids (AC). Few reports have reviewed their data according to the current classification, and therefore, prognosis and standard therapy for TC and AC are still uncertain.

METHODS: From 1980 to 2001, 98 pulmonary resections have been performed for primary bronchial carcinoid tumors in our Thoracic Department of the University of Milan. We reviewed original histology using the current W.H.O. criteria and identified 88 patients with TC and 10 with AC. We reviewed the outcomes in each group.

RESULTS: The 5 year-overall survival rate was 91.9% for TC and 71% for AC. The 10-year overall survival rate was 89.7% for TC and 60% for AC. The 5-year TNM-related survival rates in the TC group were: IA-B, 100%; IIA-B, 75%; and IIIA, 50%. At 10 years, they were: IA-B, 100%; IIA-B, 75%; and IIIA, 0%. The 5-year survival rates in the AC group were: IA-B, 100%; IIA-B, 100%; and IIIA, 0%. At 10 years, they were: IA-B, 100%; IIA-B, 66%; and IIIA, 0%.

CONCLUSIONS: Prognosis is favorable for both subtypes in the early stage. Advanced stages are related to better prognosis in TC. Recurrences rate is worse in the AC subtype. Our data suggest avoiding limited resections when feasible in AC. Parenchyma-sparing resections should be encouraged in TC.




This article has been cited by other articles:


Home page
 ICVTSHome page
A. Bini, J. Brandolini, N. Cassanelli, F. Davoli, G. Dolci, F. Sellitri, and F. Stella
Typical and atypical pulmonary carcinoids: our institutional experience
Interactive CardioVascular and Thoracic Surgery, June 1, 2008; 7(3): 415 - 418.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
R. L. Young, J. D. Mitchell, C. Cool, and S. P. Nana-Sinkam
Wheezing and Exertional Dyspnea in a 25-Year-Old Mountaineer
Chest, March 1, 2008; 133(3): 820 - 825.
[Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
F. Rea, G. Rizzardi, A. Zuin, G. Marulli, S. Nicotra, R. Bulf, M. Schiavon, and F. Sartori
Outcome and surgical strategy in bronchial carcinoid tumors: single institution experience with 252 patients
Eur. J. Cardiothorac. Surg., February 1, 2007; 31(2): 186 - 191.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
M. Garcia-Yuste, J. M. Matilla, A. Cueto, J. M. R. Paniagua, G. Ramos, M. A. Canizares, I. Muguruza, and Members of the Spanish Multi-centric Study of Neur
Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung
Eur. J. Cardiothorac. Surg., February 1, 2007; 31(2): 192 - 197.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
L. Bertoletti, R. Elleuch, D. Kaczmarek, R. Jean-Francois, and J. M. Vergnon
Bronchoscopic cryotherapy treatment of isolated endoluminal typical carcinoid tumor.
Chest, November 1, 2006; 130(5): 1405 - 1411.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
T. C. Mineo, G. Guggino, D. Mineo, G. Vanni, and V. Ambrogi
Relevance of Lymph Node Micrometastases in Radically Resected Endobronchial Carcinoid Tumors
Ann. Thorac. Surg., August 1, 2005; 80(2): 428 - 432.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. E. Ippolito, J. Xu, S. Jain, K. Moulder, S. Mennerick, J. R. Crowley, R. R. Townsend, and J. I. Gordon
An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers
PNAS, July 12, 2005; 102(28): 9901 - 9906.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Zaffaroni, R. Villa, U. Pastorino, R. Cirincione, M. Incarbone, M. Alloisio, M. Curto, S. Pilotti, and M. G. Daidone
Lack of Telomerase Activity in Lung Carcinoids Is Dependent on Human Telomerase Reverse Transcriptase Transcription and Alternative Splicing and Is Associated with Long Telomeres
Clin. Cancer Res., April 15, 2005; 11(8): 2832 - 2839.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2003 by The Society of Thoracic Surgeons.